Beneficial and adverse effects of bosentan treatment in Korean patients with pulmonary artery hypertension

Korean Circulation Journal

Volumn 39, Issue 3, 2009, Pages 105-110

  Sohn, Dae Won ^a   Kim, Hyung Kwan ^a   Kim, Myung A ^a   Song, Yeong Wook ^a   Noh, Chung Il ^a   Kim, Duk Kyung ^b   Kang, I Seok ^b   Kim, Hojoong Kim ^b   Lee, Sang Do ^c   Kim, Young Hwue ^c   Youn, Ho Joong ^d   Chung, Namsik ^e   Choi, Jae Young ^e   Jun, Jae Bum ^f   Shin, Jinho ^f  

^a Seoul National University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Hanyang University College of Medicine   (South Korea)

Author keywords

Adverse effects; Bosentan; Hypertension; Pulmonary

Indexed keywords

BOSENTAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HUMAN; KOREA; LIVER FUNCTION; LUNG ARTERY PRESSURE; MALE; MEDICAL DECISION MAKING; PATIENT MONITORING; PULMONARY HYPERTENSION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRICUSPID VALVE; WALKING;

EID: 63649157888     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2009.39.3.105     Document Type: Article

References (24)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-7.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry, Ann Intern Med 1991;115:343-9.
3. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
4. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31.
5. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
6. Rubens C, Ewert R, Halank M, et al. Big endthelin-1 and endothelin-1 plasma levels are correlated with severity of primary pulmonary hypertension. Chest 2001;120:1562-9.
7. Channnick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
9. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
10. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25:2243-78.
11. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
12. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43 (12 Suppl S):81S-8S.
13. Kim HK, Kim YJ, Park JS, et al. Determinants of the severity of functional tricuspid regurgitation. Am J Cardiol 2006;98:236-42.
14. Sagie A, Schwammenthal E, Padial LF, Vazquez de Prada JA, Weyman AE, Levine RA. Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients. J Am Coll Cardiol 1994;24:446-53.
15. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990;66:493-6.
16. Hinderliter AL, Willis PW 4th, Barst RJ, et al. Effect of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
17. Hinderliter AL, Willis PW 4th, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol 1999;84:481-4.
18. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
19. Sitbon O, McLaughlin W, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-30.
20. Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005;69:131-7.
21. Sasayama S, Satoh T, Izumi T, Yoshida S, Kyotani S, Tahara N. Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. Curr Med Res Opin 2007;23: 395-400.
22. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr 1999;12:655-62.
23. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
24. Galié N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin- receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-6.